Diabetes is rapidly increasing in India, affecting over 101 million people, often manifesting differently than in the West. Indians tend to...

India faces a significant diabetes crisis, with millions undiagnosed, increasing the risk of heart disease. Early detection through screeni...

A Lancet Global Health study reveals that nearly 40% of Indian diabetics are unaware of their condition, with a 20% prevalence among adults...

India faces a significant diabetes challenge, with high prevalence, underdiagnosis, and poor control contributing to early complications an...

Statistics show low treatment target compliance among Indian diabetes patients, increasing heart disease risks. Timely screening and weight...

According to WHO, around 9 mn people were living with type -1 diabetes in 2017.

The guidelines have mentioned about the burden of diabetes increased among the young population in India, type 1 diabetes is commonest in c...

Dr V Mohan began researching on diabetes with his father, Prof. M. Viswanathan, when he was just 18.

An expert committee under All India Institute of Medical Sciences director Randeep Guleria which worked on a formula assessed the severity ...

The drug is the first medicine in SGLT-2i class to move into a new disease area by demonstrating efficacy and safety data for the treatment...

Young girls, who are physically active and nutritionally aware, will not only improve their long-term health outcomes, but will also ensure...

The economic burden of diabetes is high in India as most patients pay out-of-pocket, and due to lack of medical reimbursement.

A completely new drug in the 'gliptin' family has disrupted the anti-diabetes market by lowering the cost of therapy for patients by 80%.

A new anti-diabetes drug from the 'gliptin' family soon to be launched in India promises to lower treatment cost for patients by 55-60%.

At the first stage, the company will bring out kits for diabetes and oncology, slated to be in the market in a year.

India, which is home to the largest diabetic population in the world, has recorded a 17% rise in the anti-diabetic drug segment.

Wipro Consumer care, a unit of Wipro Limited, on Friday launched a low-calorie sugar substitute, stepping into the Rs 75-crore low calorie ...